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Background: The most common cystic fibrosis (CF) manifestation is the progressive chronic obstructive pulmonary
disease caused by deficiency, dysfunction, or absence of the CFTR (Cystic Fibrosis Transmembrane Regulator)
protein on the apical surface of the cells in the respiratory tract. The use of bronchodilators (BD), and inhaled
corticosteroids (IC) have been suggested for the management of airway inflammation in CF. The effectiveness of BD
and IC have been verified, proven in laboratory and in the clinical treatment for asthma patients. However, in CF,
the effectiveness of these drugs is controversial. The extent of asthma’s response to BD depends on the presence
of polymorphisms in the ADRB2 gene. In contrast, in CF, little is known about the response to the BD and the
association of CF´s severity with the different polymorphisms in ADRB2 gene. In this context, our objective was to
verify whether the Arg16Gly and Glu27Gln polymorphisms in ADRB2 gene are associated with severity and with the
bronchodilator response in CF patients.
Method: Cross-sectional study of 122 CF patients subjected to analysis of mutations in the CFTR gene,
polymorphisms in ADRB2 gene, along with clinical and laboratorial characteristics of severity.
Result: The Arg16Gly polymorphism in ADRB2 gene was associated with pancreatic insufficiency(p:0.009), Bhalla
score(p:0.039), forced expiratory volume in the first second[FEV1(%)](p:0.003), forced expiratory flow between 25 and
75% of the forced vital capacity-FVC[FEF25-75(%)](p:0.008) and lower age at the first isolation of the Pseudomonas
aeruginosa(p:0.012). The response to the BD spirometry was associated with clinical severity markers, FEV1(%)
(p:0.011) and FEF25-75(%)(p:0.019), for the Arg16Gly polymorphism in the ADRB2 gene. The haplotype analysis
showed association with the FEV1/FVC marker from the spirometry test, before and after using the BD, with higher
values in the group with Gly/Gly and Glu/Glu, respectively, for the Arg16Gly and Gln27Glu polymorphisms. The
analysis by MDR2.0 software, showed association with FEF25-75%; the response to Arg16Gly was respondent by
17.35% and Gln27Glu by 6.8% in variation found.
Conclusion: There was an association between the Arg16Gly and Gln27Glu polymorphisms in ADRB2 gene with
CF´s severity and bronchodilator response.
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Studies have confirmed the mechanisms though which
cystic fibrosis (CF) patients with similar mutations show
significantly different signs and symptoms [1-4]. Even
among homozygous for classes I, II and/or III mutations,
the disease's clinical expression may be very different.
Explanations for these broad clinical variations included
environmental factors [5], medical management [3], nu-
trient intake [6], psychological [7], economic situations
[3], and classes of mutations and polymorphisms in
modifier genes [2-4].
Unlike most patients with asthma, the inflammation in
CF is predominantly neutrophilic [8], with an intense in-
flammatory component and lower rate of bronchial
hyper responsiveness [9]. In contrast, inhaled broncho-
dilator (BD) has been used for the management of these
two conditions [10]. In addition to the BD, β-agonists
affect the other functions of the airways: they reduce in-
flammatory cells mediators release, cholinergic neuro-
transmission and vascular permeability, as well as
increase the clearance mucociliary [11], features that jus-
tify its use in CF.
Studies regarding the BD asthma response have
revealed different results, depending on the polymorph-
ism in ADRB2 gene [12]. The physical and chemical
characteristics of the β2 (β2-AR) receptors are found in
scientific literature, and demonstrate its importance to
many biological processes, including muscle relaxation
in the lungs [13-15]. Among polymorphisms identified
in coding region of the ADRB2 gene, the Arg16Gly
(c.46A > G) and Gln27Glu (c.79C > G) are the most
studied in asthma [12]. The Gln27Glu polymorphism
confers resistance from the ADRB2 protein to BD ac-
tion. The ADBR2*G allele is protective against asthma,
reducing its risks by 27% [13]. ADBR2*G induces
changes in receptor regulation, which occurs due to its
increased susceptibility to the protein's degradation.
Haplotypes that include the ADBR2*A allele have
better response to the inhaled β2 agonists. Presumably,
better response to exogenous agonists reflects better re-
sponse to endogenous agonists and a protective effect
against asthma and other bronchial hyper responsiveness
diseases [16]. Haplotypes with two Arg16Gly/Gln27Glu
mutant receivers showed that the effects of the Arg16-
Gly predominate over the Gln27Glu. These receptors
are subject to greater regulation by agonists than the
normal allele from the β2-AR receptor [13].
The effectiveness of BD and IC have been attained and
proven in both the laboratory and the clinical treatment
for asthma patients. Nevertheless, with CF the effective-
ness of these drugs is controversial. The effectiveness of
asthma’s response to the BD is dependent on poly-
morphisms in ADRB2 gene. In contrast, with CF, little is
known about the response to the BD and the CF´sseverity in association with the different polymorphisms
in ADRB2 gene [17-19]. Although previous studies had
showed an association between bronchodilator response
and the polymorphisms in the ADRB2 gene, these stud-
ies did not take into account secondary clinical variables
that can provide extra information about the mechanism
associated with action of the ADRB2 protein.
Recently, it was discovered that the regulation of CFTR
activity is mediated by the activation of G-coupled recep-
tors such as the β2-AR. CFTR and the β2-AR protein are
associated in a large macromolecular complex [20-22].
Taouil and colleagues showed that the long-acting salme-
terol treatment increased wild-type CFTR expression in
primary human airway epithelial cells. They demonstrated
that wild-type CFTR levels increased more than 2-fold
during this treatment, while the mRNA levels were un-
affected [21].
In this context, the aim of this study was to investigate
the influence of the Arg16Gly and Glu27Gln poly-
morphisms from the ADRB2 gene on 26 clinical severity
markers and the bronchodilator response in CF patients
from a university referral center.
Methods
A cross-sectional study was conducted in a referral cen-
ter for CF treatment, at the Campinas University Hos-
pital (UNICAMP) in 2010 and 2011. A total of 122
patients were included, with at least seven years of age
and who underwent pulmonary function tests before
and after the use of inhaled Albuterol (400 mg) accord-
ing to the American Thoracic Society (2011) [23]. The
patients underwent two perspiration tests of chlorine
and sodium with chlorine levels equal to or greater than
60 mEq/L, and/or identification of two mutations in
CFTR gene [F508del, G542X, G551D, R553X, R1162X,
I618T and N1303K]. The project was approved by the
University Ethics Committee (#528/2008), all patients
and/or their guardians signed an informed consent.
We clinically evaluated the patients according to the fol-
lowing clinical severity markers: clinical scores (Shwach-
man-Kulczycki, Kanga and Bhalla) [24]; body mass index
(BMI) [for the patients older than 19 years the BMI =
weight/(height)2 formula was used; for the remaining
patients the WHO ANTHRO PLUS (children 7-19 years
old) [25]; patient age (group: younger≤ 24 months and
older > than 24 months) and age at diagnosis (according
to the sodium and chloride in altered perspiration -
younger age group≤ 24 months and older > than
24 months); first clinical symptoms [(digestive - younger
age≤ 3 months and older > than 3 months; pulmonary -
younger age≤ 6 months and older > than 6 months)]; the
period up to 1st colonization by Pseudomonas aeruginosa
(younger≤ 31 months and older > than 31 months); pres-
ence of microorganisms in the sputum (P. aeruginosa
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Burkolderea cepacia and Staphylococcus aureus); transcu-
taneous oxygen saturation; pulmonary function tests be-
fore and after BD use and CF´s co morbidities (nasal
polyps, osteoporosis, meconium ileus, diabetes mellitus
and pancreatic insufficiency).
The Spirometry proof was performed using a speedom-
eter model CPFS/D (Med Graphics, Saint Paul, Minnesota,
USA). Data were recorded by the BREEZE PF Version 3.8
B software for Windows 95/98/NT with inclusion of the
following markers: forced vital capacity - FVC(%), forced
expiratory volume in the first second - FEV1(%), ratio be-
tween the FEV1 and the FVC, and forced expiratory flow
between 25-75% of the FVC (FEF25-75%). All patients
underwent spirometry test before and after 15 minutes of
the BD - albuterol (400 mg) administration. Patients receiv-
ing the BD therapy were instructed to stop the medication
8 hours prior to the short-acting beta agonist spirometry
test and 48 hours prior to the long-acting beta agonist [23].
Genomic DNA was extracted using phenol-chloroform
from venous blood samples. Polymorphism analysis in
modifier genes was performed by the polymerase (PCR)
allele specific (ARMS) reaction, according to Littlejohn
et al. (2002) [26]. Four reactions were performed,
(ARMS1a, ARMS2a, and ARMS1b ARMS2b), each con-
taining a common primer and one specific allele. All
four reactions were performed under the same condi-
tions. Each consisting of a total of 10μL containing 1x4
PCR buffer, 200 μM dNTPs, 5.0nM MgCl2, 0.4U of Taq
polymerase, 0.2 pMoles of each primer and 1.0μL
(approximately 50 ng) of genomic DNA. The PCR amp-
lification conditions consisted of 5 min at 94°C followed
by 35 cycles of 94°C for 1 min, 60°C (46 A or G - 16 Arg
or Gly), or 67°C (70°C or G - 27 Gln or Glu), 72°C for
1 minute and 72°C for 10 min. The amplicons were sub-
mitted to electrophoresis on 12% acryl amide gel and
stained with ethidium bromide for visualization of the
results.
Statistical analysis of the data
Statistical analysis was performed by the software SPSS
v.17.0 (SPSS Inc., Chicago, IL, USA) [27], Epi Info v.6.0
[28] and R version 2.12 (Comprehensive R Archive Net-
work, 2011). The statistical power calculation for the
sample was performed by the GPOWER 3.0.5 software
[29] demonstrating statistical power above 80% for the
conducted analysis. Alpha = 0.05 was used in all data
analyses.
Analysis of variance (ANOVA) and chi-squared (2) -
Odds Ratio (OR) tests were performed for quantitative
and categorical variables, respectively. Pulmonary
function comparison data before and after the BD use
was performed by the ANOVA test; subsequently, the
different genotypes for the Arg16Gly and Gln27Glupolymorphisms in ADRB2 gene were analyzed by the
Student’s t test. Supplementary analysis performed by
MDR software 2.0 (Multifactor dimensionality Reduction
- Norris-Cotton Cancer Center, 2008) and MDRPT 0.4.7
(Permutation Test Multifactor dimensionality Reduction
- Norris-Cotton Cancer Center, 2008), to evaluate the
influence of both polymorphisms with the variation in
the spirometry values of the bronchospasm response.
The analyses of subgroups by age were not possible in
our population as subgroups had a small number of
patients.
In order to avoid spurious data due to the multiple
tests problematic [30], the significance level α was
adjusted by the Bonferroni correction (α corrected =
0.05/number of tests).
Results
The frequencies of each genotype for the Arg16Gly poly-
morphism was: 23(18.85%), 54(44.26%) and 45(36.89%),
respectively for the Arg/Arg, Arg/Gly and Gly/Gly. For
the Gln27Glu polymorphism was 61(50.00%), 51
(41.80%) and 10(8.20%), respectively for the Gln/Gln,
Gln/Glu and Glu/Glu. The population is within the
Hardy-Weinberg equilibrium (2 = 0.88, p > 0.05; 2 = 0.02;
p > 0.05, respectively for the Arg16Gly and Gln27Glu
polymorphisms in ADRB2 gene). The patients' charac-
teristics included in the study are described in Table 1.
The Arg16Gly polymorphism in ADRB2 gene, without
the distribution by the CFTR gene genotype, was asso-
ciated with the FEV1(%) (p = 0.003) and FEF25-75%
(p = 0.008), the minor value was observed in patients
with Arg/Arg genotype. Patients with no identified mu-
tation in CFTR gene were associated with better value to
FEF25-75% to Gly/Gly genotype (p = 0.008). The group
with two mutations identified in CFTR gene was asso-
ciated with bigger value to Bhalla score to Arg/Arg
genotype (p = 0.04) (Figure 1). In this same patients’
group there was association with the pancreatic insuffi-
ciency, and the Arg/Arg genotype with an OR of 0.13
(95%CI = 0.03-0.86) and Gly/Gly with an OR of 8
(95%CI = 1.95-67.7) with the presence of co morbidity
and with the first isolated P. aeruginosa, OR of 0.22
(95%CI = 0.05-0.99) for the Gly/Gly genotype.
The Gln27Glu polymorphism in ADRB2 gene showed
no statistically significant association with the variables
used as CF´s severity markers in this study.
The analysis of the polymorphisms in ADRB2 gene
and their association with BD mediated bronchospasm
response occurred for the Arg16Gly polymorphism
(Table 2). The variables demonstrating modulations
were: FEV1(%) (p = 0.01) and FEF25-75% (p = 0.02)
(Figure 2). The Gly/Gly genotype was associated with a
minor bronchodilator response. The variation values
data for the spirometry test markers according to the
Table 1 Characteristics of patients included in the study
(N= 122)1
Male 48.8 %
Age 246.68 ± 168,73 months
(87 - 932 months)
Caucasoid 93.4%
BMI - Thinness and
Thinness accentuated
22.3%
SaO2 94.87 ± 4.53 (66 – 99)
Bhalla 9.41 ± 5.57 (0 – 25)
Kanga 19.37 ± 5.01 (11 – 40)
Shwachman-Kulczycki 65.41 ± 16.02 (20 – 95)
FVC (%) 78.27 ± 22.86 (19 – 135)
FEV1 (%) 70.28 ± 26.17 (17 – 125)
FEV1/FVC (%) 83.83 ± 15.79 (37 – 137)
FEF25-75% 58.50 ± 34.83 (7 – 150)
FVC (%) reversibility 0.92 ± 10.48 (-27 – 32)
FEV1 (%) reversibility 2.15 ± 9.45 (-12 – 31)
FEV1/FVC (%) reversibility 2.84 ± 9.69 (-19 – 47)






P. aeruginosa status 2 53.7%
P. aeruginosa mucoid status 2 45.5%
B. cepacia status 2 9.1%
A. xylosoxidans status 2 9.9%









F508del/No identified mutation 26 (21.5%)
G542X/No identified mutation 4 (3.3%)
No identified mutation 43 (35.3%)
N - Sample size; BMI - body mass index; % - percentage; FVC - forced vital
capacity; FEV1 - forced expiratory volume in the first second;
FEF25-75% - forced expiratory flow between 25 and 75% of CVF. 1.
Continuous variables expressed as mean ± SD (range). 2. Based on 3
consecutive positive respiratory cultures.
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Gln27Glu polymorphisms are described in Table 3. In
the haplotypes analysis the groups with the GG genotype
were considered in at least one, both, or in none of the
polymorphisms analyzed.The statistical analysis performed by the MDR 2.0 pro-
gram in comparison with the curve stipulated by the
data held by the MDRPT 0.4.7 program, demonstrated
the influence of the two polymorphisms analyzed with
the variance of FEF25-75% before and after using the BD
[Bal Acc. testing.: 0.772, p: 0.0034, ratio: 0.9934]. From
the observed variation for the FEF25-75%, according to
the test performed, the Arg16Gly polymorphism is re-
sponsible for 17.4% and the Gln27Glu for 6.8% of the
variation.
Discussion
In the last decade, several studies have shown that the
receptor for beta 2 agonist is intimately connected, phys-
ically and functionally, to the CFTR protein on the
surface of the epithelial cells in the airways [20]. Inter-
estingly, the function of this complex behaves differently
if the stimulus is caused by long or short term beta 2
agonist substances [20-22]. The clinical response of the
CF patients in relation to the long-term beta agonists in
the different polymorphisms in ADRB2 gene has not
been studied, while for the short term use, there are few
studies in the literature [17-19]. With asthma, the
Arg16Gly and Gln27Glu polymorphisms in ADRB2 gene
cause different reactions to the Bronchodilation pro-
moted by BD [12]; however, little is known about their
impact on the severity and response to Bronchodilation
caused by CF BD [17-19].
To the best of our knowledge it is known that the
allele frequency for the Arg16Gly and Gln27Glu poly-
morphisms in ADRB2 gene is different in adults and
children with CF [19]. Adult patients with CF have a
higher frequency for the Gly16 and Glu27 alleles com-
pared to people CF free. Children with CF have a lower
frequency for Gly16 and similar with the Glu27. Young
adults with CF in relation to the variant forms in ADRB2
gene did not differ from the population in general. In
our population there was no difference in genotype dis-
tribution for the Arg16Gly (p:0.92) and Gln27Glu
(p:0.88) polymorphisms in ADRB2 gene relative to the
patients' age group.
Our study showed an association of the Arg16Gly
polymorphism in ADRB2 gene with the severity of CF
markers. The variation in the spirometry proof before
and after the use of BD was associated with the Arg16-
Gly and Gln27Glu polymorphisms in ADRB2 gene.
Twenty six of CF´s severity markers were used in the
study; and the response to Bronchodilation was assessed
by four spirometry markers.
Hart et al. (2005) [18] used the FEV1(%) and the
FEF25-75% as severity markers, in addition to the fol-
lowing variables adjustment: age, gender, the F508del
homozygous and Pseudomonas aeruginosa status.































Figure 1 Bhalla score and spirometry values in Cystic Fibrosis patients modulated by polymorphism in ADRB2 gene. Association of the
cystic fibrosis severity with polymorphism Arg16Gly in ADRB2 gene. A. Bloxplot of the Bhalla score in patients with two identified mutations in
CFTR gene. The Bhalla score data is a gross value. # p:0.011; * p:0.779; ¥ p:0.007. B. Bloxplot of FEV1(%) in patients without taking CFTR mutation
into account. # p:0.007; * p:0.277; ¥ p:0.003. C. Bloxplot of FEF25-75% in patients without without taking CFTR mutation into account. # p:0.038; *
p:0.43; ¥ p:0.015. D. Bloxplot of FEF25-75% in patients with no mutations identified in CFTR gene. # p:0.933; * p:0.008; ¥ p:0.001. The data of the
spirometry are in percentage of the predicted population value. The test used for the analyses was the T´student test.
Marson et al. BMC Pulmonary Medicine 2012, 12:50 Page 5 of 9
http://www.biomedcentral.com/1471-2466/12/50FEV1, FVC, flow at lower lung volumes (MEF50%VC),
measurement of cAMP accumulation in intact mono-
nuclear lymphocytes, age, gender, BMI, F508del homozy-
gous and Pseudomonas aeruginosa status. Hart et al.
(2005) [18] considered the presence of values 12% higher
in the FEV1 after using the BD, (the examination of spir-
ometry occurred 15 minutes after administration of BD),
a positive response to Bronchodilation, while Buscheret al. (2002) [17] believed in the 10% variation for the
same marker (the Spirometry test occurred 5 minutes
after BD administration). Steagall et al. (2007) [19] used
as markers: age, sex, F508del status, carbon monoxide
diffusing capacity (DLCO), FEV1(%) and the FVC(%).
The positive response to Bronchodilation was seen as a
positive variation superior to 12% for the FEV1 and the
FVC spirometry markers.
Table 2 Association of polymorphisms in ADRB2 gene with spirometry of Cystic Fibrosis patients1
Variable Arg16Gly Gln27Glu
Arg/Arg Arg/Gly Gly/Gly F p Gln/Gln Gln/Glu Glu/Glu F p
FVC (%) 23 (82.04 ± 4.48) 54(79.30 ± 3.21) 44(75.05± 3.43) 3.25 0.08 63(77.9 ± 2.92) 48(79± 3.37) 10(77.1 ± 6.48) 0.02 0.90
FEV1 (%) 23(72 ± 5.57) 53(72.57± 3.47) 44(66.64± 4.10) 6.80 0.01 62(70.34± 3.49) 48(70.75 ± 3.63) 10(67.70 ± 8) 0.45 0.50
FEV1/FVC 23(82 ± 4.27) 52(84.79 ± 1.82) 44(83.33± 2.44) 1.12 0.29 62(85.32 ± 1.9) 47(82.21 ± 2.48) 10(82.20 ± 4.96) 0.17 0.68
FEF25-75% 23(58.17 ± 7.22) 53(59.91± 4.48) 44(56.98± 5.75) 5.82 0.02 62(61.34± 4.64) 48(55.88 ± 4.84) 10(53.50 ± 9.99) 1.23 0.27
% - Percentage; FVC - forced vital capacity; FEV - forced expiratory volume; FEF25-75% - forced expiratory flow between 27-75% of the FVC. 1. Continuous
variables expressed as number of patients (mean ± SD (range). Statistical analysis conducted by analysis of variance (ANOVA) through (in bold) statistically
significant values with less than 0.05.
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mutations, (belonging to the classes I, II and/or III), of
the CFTR gene, along with the polymorphisms in
ADRB2 gene were associated to different markers related
to CF´s severity.
An intriguing aspect of our study, not previously
described, were the findings that CF´s patients with two
mutations from classes I, II and/or III, Arg/Arg homozy-
gous for the Arg16Gly polymorphism, have greater
impairment of lung function than the Gly/Gly homozy-
gous, provided by the Bhalla score. And the Gly/Gly
homozygous showed higher pancreatic insufficiency than
the Arg/Arg. The two clinical variables are associated with
CF severity, and are modulated by the Gly/Gly genotype



































Figure 2 Bronchodilatador response in Cystic Fibrosis patients modul
bronchodilators by the alteration of spirometry markers values in the Cystic
gene. A. Bloxplot of the variation in the FEV1(%) before and after using bro
account. # p:0.361; * p:0.001; ¥ p:0.002. B. Bloxplot with the variation in the
without without taking CFTR mutation into account. # p:0.031; * p:0.026; ¥
from the pulmonary function test are in percentage of the predicted popuallele is associated with fast protein degradation [13] that
was identified as a severity factor.
The first isolation of the P. aeruginosa was confirmed
later in patients with the Gly/Gly genotype and two
mutations classes I, II and/or III in CFTR gene. The
early colonization is associated with clinical deterior-
ation and a greater degree of airway inflammation [31].
The response to this polymorphism and the clinical
aspects of CF´s patients has not been studied in the lit-
erature referenced, except for Buscher et al., (2002) [17],
whose analysis of some of the markers, (age, gender,
BMI and P. aeruginosa status), showed no significant as-
sociation, a fact that hampered data comparison. An-
other relevant fact is the Gln27Glu polymorphism lack



































ated by polymorphism in ADRB2 gene. Response to the inhaler
Fibrosis patients according to polymorphism Arg16Gly in ADRB2
nchodilators in patients without without taking CFTR mutation into
FEF25-75(%) before and after using bronchodilators in patients
p:0.01. Analysis made group by group by the T´student test. The data
lation value.
Table 3 Change in FVC, FEV1, and FEF25-75 FEF1/FVC post-bronchodilator by ADRB2 haplotype
1
Arg16Gly/Gln27Glu GG haplotype group p-
value0 GG (n= 56) 1 GG (n = 34) 2 GG (n = 4)
Change in FVC(%) -0.17 ± 9.86 2.29 ± 11.87 5.25 ± 4.03 0.17
Change in FEV1(%) 2.10 ± 9.42 2.18 ± 9.57 2.75 ± 11.41 0.92
Change in FEV1/FVC(%) 4.61± 10.45 0.53± 7.75 -2.25± 9.61 0.02
Change FEF25-75(%) 6.36 ± 30.75 8.62 ± 41.75 8 ± 39.45 0.79
% - Percentage; FVC - forced vital capacity; FEV - forced expiratory volume; FEF25-75% - forced expiratory flow between 27-75% of the FVC. Statistical analysis
performed by linear regression. 1. Percent change calculated as 100 x (post-bronchodilator value – pre-bronchodilator value)/pre-bronchodilator value.
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this polymorphism as a modulator of CF´s severity.
Our results show that CF´s patients with the Arg/Arg
genotype from the Arg16Gly polymorphism have lower
values of the FEV1 and FEF25-75%. The observation
contrasts with the data from Buscher et al. (2002) [17]
who reported higher values of the Arg/Arg genotype in
87 CF´s patients for the FEV1, FVC, and MEF50%VC
markers, when compared with subjects with a genotype
containing at least one Gly allele. The same was
observed when the genotype for the delF508 mutation
was used; 51 patients were analyzed, and higher values
for the markers were found for the same genotype.
In our data the Gln27Glu polymorphism in ADRB2
gene was not associated with spirometry markers. Di-
versely, in the Buscher et al. (2002) [17] study, the Gln/
Gln genotype for the Gln27Glu polymorphism, when
compared with the others, showed a higher correlation
for the FEV1, FVC, and MEF50%VC values. In the
Steagall et al. (2007) [19] study there was no correlation
between the DLCO, FEV1 and the FVC in patients with
homozygous F508del stratified by the Arg16Gly and
Gln27Glu polymorphisms genotype in ADRB2 gene.
The patients with no identified mutations in CFTR
gene, in our study, showed higher values in the FEF25-
75% for the Gly/Gly genotype. Thus, comparing the data
discussed above, we denote the influence of the Arg16-
Gly polymorphism in ADRB2 gene that occurs in the
spirometry, and that is also influenced by the genotype
in the CFTR gene.
We found that the Arg27Gly polymorphism in ADRB2
gene was associated with the bronchospasm response
mediated by beta 2 agonists. The FEV1(%) variation was
lower in patients with the Gly/Gly genotype, when com-
pared with the Arg/Arg and Arg/Gly genotypes. The
FEF25-75% was lower in patients with the Gly/Gly geno-
type when compared to the Arg/Arg and Arg/Gly.
Patients with the Arg/Arg genotype showed higher
FEF25-75% when compared to the Arg/Gly genotype.
In the study by Hart et al. (2005) [18], one hundred
and six patients with CF underwent spirometry before
and after the BD administration, and the Arg16Gly and
Gln27Glu polymorphisms genotype was determined.
The positive response was observed in 15% (23/154) ofthe included patients and 17% (18/106) among the
patients who had genotype for the gene ADBR2 deter-
mined. There was no significant relationship between
the ADRB2 gene genotype for the Arg16Gly and
Gln27Glu polymorphisms and the response to the BD
[18]. However, after the FEV1 adjustment in percentage
for the predicted and the status of infection by the
P. aeruginosa, a significant difference occurred to the
FEF25-75% percentage of change (4.9%, 18.0% and 22.4%
for the genotypes AA, AG and GG; respectively). The
FEF25-75% percentage of change showed no substantial
difference for the codon 27, even after the adjustment
for the infection by P. aeruginosa and by the predicted
baseline of FEV1(%) [18]. After adjusting the FEV1 per-
centage predicted baseline, the codon 27 groups differed
significantly from the percentage of change in the FEV1
(%) (4.1%, 8.1% and 9.3% for the genotypes CC, CG and
GG; respectively) [18]. The authors suggested that the
effect of the two polymorphisms were complex and the
haplotype analysis may be more informative than any
genotype alone [18]. To that effect, a large number of
patients would be needed, only possible in multi-centric
studies. Then again, in multi-centric studies the environ-
ment and diverse management systems could provide
significant bias in the clinical severity outcome.
In the study by Buscher et al. (2002) [17], no statisti-
cally significant difference was found for the FEV1 aver-
age value and in the absolute number of patients with
positive response to BD among the Arg16Gly poly-
morphism genotypes in ADRB2 gene.
In the Steagall et al. (2007) [19] study homozygous
patients with the delF508 mutation were analyzed for
their reactions to Bronchodilation. Patients who showed
no response to the Bronchodilation had, on average,
higher values in the FVC and FEV1 for the Arg/Arg
genotype in the Arg16Gly polymorphism of the ADRB2
gene when compared to other genotypes; however, in
the analyzed group there were only two patients with
the Arg/Arg and two with the delF508 mutations for the
CFTR gene. For the Gln27Glu polymorphism, the Gln/
Gln genotype was associated with higher FVC values. In
the responders group only the Gln27Glu polymorphism
was associated with higher values of the DLCO, FVC
and FEV1 for the Gln/Glu genotype. In our study, the
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pulmonary function test with the BD use, and the distri-
bution by the polymorphisms in ADRB2 gene and muta-
tions in classes I, II and/or III, was performed, but the
sample power was less than 80%.
The long term decline in spirometry values was not
evaluated in this study, even though it presents a promis-
ing field of study, verified by Buscher et al. (2002) [17]
who demonstrated that, in 59 CF patients aged 6-20 years,
the biggest FEV1 decline was in patients with at least one
Gly allele, while no change in pulmonary function was
seen in patients homozygous for Arg.
The genic interaction analysis performed by the MDR
2.0 program showed a combination of both polymorph-
isms with the variation for the FEF25-75% but not to
other markers of severity. Thus, this corroborates that
the polymorphisms in ADRB2 gene influence the Bron-
chodilation response.
In the haplotypes analysis the Ar/Arg + Gln/Gln presence
was associated with the best response to Bronchodilation
for the marker FEV1/FVC (N=56; +4.61%±10.45), when
compared to the other groups: 1 GG [Arg/Arg + Glu/Glu,
Arg/Gly + Glu/Glu, Gly/Gly + Gln/Gln, Gly/Gly + Gln/Glu
(N=34; +0.53%±7.75)] and 2 GG [Gly/Gly + Glu/Glu
(N=4; -2.25%±9.605)]. In the study by Hart et al. (2005)
[18], the haplotypes analysis for three different models
demonstrated association with the FEV1 marker. And the
values of 4.4 (± 5.8), 7.9 (± 8.7) and 9.0 (± 5.8); respectively
to 0 GG (N=27), 1GG (N=64) and 2GG (N=15), with
p values equal to 0.033, 0.027 and 0.305; respectively for the
models, additive, dominant and recessive.
In our results, the bronchodilator response was reduced
with the presence of the variants with Gly or Glu allele, a
fact contrary to that reported by Hart et al. (2005) [18].
Possible limitations of our study included: sample size,
different age groups, and different severities of lung dis-
ease that could express differences in the BD response.
Our data can provide better understanding about the
association between polymorphism associated with
β2-AR protein and the clinical markers of CF´s severity,
and others studies about the large macromolecular com-
plex are necessary to improve knowledge about the
interaction of the proteins on the bronchial epithelial
surface.
Conclusion
The influence of polymorphisms in the CF´s severity
and bronchospasm response is controversial in the sci-
entific literature, and seldom studied. Our results sup-
port the idea that differences in the degree of airway
responsiveness to the BD may be associated with the
ADRB2 gene genotype in the CF. Arg16Gly and
Gln27Glu polymorphisms are associated with the re-
sponse to the Bronchodilation. For the spirometry andother clinical variables of severity; the Arg16Gly poly-
morphism showed statistically significant association; di-
versely, the Gln27Glu showed no association. The Arg/
Arg genotype to Arg16Gly polymorphism was associated
with a better spirometry to FEV1(%) and FEF25-75%
clinical markers and minor risk to PI, in comparison
with other genotypes. To bronchodilator response the
haplotype data to the polymorphism show association
with positive response to beta 2 agonists to absence of
genotypes Gly16Gly and Glu27Glu to FEV1/FVC(%)
marker.
We must pay attention to the need for more studies;
with the suppressed polymorphisms and their associ-
ation with the clinical severity variables using a larger
number of CF´s patients with the same CFTR genotype
for the mutation classes I, II and/or III; also patients
with the same degree of change in the spirometry test to
analyze the response to Bronchodilation.
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